UBS Group’s Iterum Therapeutics ITRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.76K | Buy |
8,799
+100
| +1% | +$99 | ﹤0.01% | 7604 |
|
|
2025
Q1 | $10.7K | Buy |
8,699
+5,625
| +183% | +$6.92K | ﹤0.01% | 7296 |
|
|
2024
Q4 | $5.44K | Buy |
3,074
+3,073
| +307,300% | +$5.44K | ﹤0.01% | 7421 |
|
|
2024
Q3 | $1 | Hold |
1
| – | – | ﹤0.01% | 8205 |
|
|
2024
Q2 | $1 | Sell |
1
-12,018
| -100% | -$12K | ﹤0.01% | 8268 |
|
|
2024
Q1 | $18.5K | Buy |
12,019
+7,070
| +143% | +$10.9K | ﹤0.01% | 5784 |
|
|
2023
Q4 | $9.75K | Buy |
+4,949
| New | +$9.75K | ﹤0.01% | 6264 |
|
|
2023
Q3 | – | Sell |
-48
| Closed | -$51 | – | 8490 |
|
|
2023
Q2 | $51 | Buy |
48
+42
| +700% | +$45 | ﹤0.01% | 7512 |
|
|
2023
Q1 | $6 | Sell |
6
-15,258
| -100% | -$15.3K | ﹤0.01% | 8379 |
|
|
2022
Q4 | $12.8K | Buy |
15,264
+6,943
| +83% | +$5.83K | ﹤0.01% | 7042 |
|
|
2022
Q3 | $13K | Buy |
+8,321
| New | +$13K | ﹤0.01% | 6940 |
|
|
2022
Q2 | – | Sell |
-1,966
| Closed | -$10K | – | 9479 |
|
|
2022
Q1 | $10K | Sell |
1,966
-2,368
| -55% | -$12K | ﹤0.01% | 7362 |
|
|
2021
Q4 | $25K | Buy |
4,334
+3,528
| +438% | +$20.4K | ﹤0.01% | 6472 |
|
|
2021
Q3 | $7K | Sell |
806
-1,143
| -59% | -$9.93K | ﹤0.01% | 7162 |
|
|
2021
Q2 | $68K | Sell |
1,949
-1,582
| -45% | -$55.2K | ﹤0.01% | 5112 |
|
|
2021
Q1 | $75K | Buy |
+3,531
| New | +$75K | ﹤0.01% | 5189 |
|
|
2020
Q2 | – | Sell |
-833
| Closed | -$34K | – | 7184 |
|
|
2020
Q1 | $34K | Buy |
833
+703
| +541% | +$28.7K | ﹤0.01% | 5228 |
|
|
2019
Q4 | $9K | Sell |
130
-52
| -29% | -$3.6K | ﹤0.01% | 6258 |
|
|
2019
Q3 | $16K | Buy |
182
+179
| +5,967% | +$15.7K | ﹤0.01% | 5909 |
|
|
2019
Q2 | $0 | Buy |
+3
| New | – | ﹤0.01% | 7045 |
|
|
2019
Q1 | – | Sell |
-9
| Closed | -$1K | – | 6970 |
|
|
2018
Q4 | $1K | Buy |
+9
| New | +$1K | ﹤0.01% | 6960 |
|